Risperidone - Mapi Pharma

Drug Profile

Risperidone - Mapi Pharma

Alternative Names: Risperidone LAI; Risperidone LAI - Mapi Pharma; Risperidone LAI+

Latest Information Update: 07 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mapi Pharma
  • Developer Jiangsu Nhwa Pharmaceutical; Mapi Pharma
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Schizophrenia
  • Preclinical Bipolar disorders

Most Recent Events

  • 27 Oct 2016 Chemical structure information added
  • 25 Oct 2016 Phase-I clinical trials in Schizophrenia in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top